牛牛AI助理已提取核心訊息
Bradley Saenger, the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), has engaged in a transaction involving the company's stock. The action took place on February 27, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Saenger after the transaction was not provided. This information is typically crucial for investors to assess the significance of insider transactions within a company.
Bradley Saenger, the Chief Financial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP), has engaged in a transaction involving the company's stock. The action took place on February 27, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Saenger after the transaction was not provided. This information is typically crucial for investors to assess the significance of insider transactions within a company.
Tonix Pharmicals Holding Corp.（TNXP）首席財務官布拉德利·桑格參與了一項涉及該公司股票的交易。該行動於 2024 年 2 月 27 日進行。但是，該公告沒有透露交易的股票數量、股票的性質、交易價格或股票的總價值。此外，沒有提供Saenger在交易後持有的股票數量。這些信息通常對於投資者評估公司內部交易的重要性至關重要。
Tonix Pharmicals Holding Corp.（TNXP）首席財務官布拉德利·桑格參與了一項涉及該公司股票的交易。該行動於 2024 年 2 月 27 日進行。但是，該公告沒有透露交易的股票數量、股票的性質、交易價格或股票的總價值。此外，沒有提供Saenger在交易後持有的股票數量。這些信息通常對於投資者評估公司內部交易的重要性至關重要。
有用
沒用